🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 receptor expression in cardiac tissue — cardioprotection mechanisms Page 3

GLP-1 receptor expression in cardiac tissue — cardioprotection mechanisms

Dr.CardioMD Sat, May 30, 2026 at 10:12 AM 20 replies 580 viewsPage 3 of 4
FranDenver
Member
267
1,123
Oct 2024
Denver, CO
May 31, 2026 at 3:12 AM#11
TinaHashiRN said:
I want to add the drug interaction perspective on the pharmacology.

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: May 31, 2026 at 9:12 AM
9 7Dr.RenalNash, LipidDoc_ATL, BariatricNurseD and 6 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
May 31, 2026 at 2:42 PM#12

Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

10 8BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 7 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jun 1, 2026 at 2:12 AM#13
NurseKim_ATL said:
Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

Last edited: Jun 1, 2026 at 3:12 AM
11 9tampaLisa73, KarenAZ_mom, zoe_NC and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Jun 1, 2026 at 1:42 PM#14

One concrete data point for the thread. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

12 10SaraMom3, Dr.MetabolicMD, RetaRick_CA and 9 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 2, 2026 at 1:13 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.

13 11PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 10 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register